Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting

BACKGROUND: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains l...

Descripción completa

Detalles Bibliográficos
Autores principales: Assié, Jean-Baptiste, Chouaïd, Christos, Nunes, Hilario, Reynaud, Dorothée, Gaudin, Anne-Françoise, Grumberg, Valentine, Jolivel, Ronan, Jouaneton, Baptiste, Cotté, François-Emery, Duchemann, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893351/
https://www.ncbi.nlm.nih.gov/pubmed/36743523
http://dx.doi.org/10.1177/17588359231152847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893351/
https://www.ncbi.nlm.nih.gov/pubmed/36743523
http://dx.doi.org/10.1177/17588359231152847

Ejemplares similares